Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
'Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'He has effectively supported our strategic priorities in a complex market environment while maintaining disciplined capital management. His deep understanding of our business will continue to be instrumental as we advance our clinical pipeline, prepare for our Biologics License Application submission for CAN-2409 in localized prostate cancer, and execute on our near- and long-term corporate goals.'
Since joining Candel in November 2021, Mr. Schoch has served in various financial reporting and accounting positions of increasing responsibility, most recently as VP of Finance and Corporate Controller, before being named interim CFO in January 2024. In his interim CFO role, Mr. Schoch developed significant investment banking relationships and has led the company through engagements with top-tier institutional investors, culminating in a previously-announced capital raise with net proceeds of approximately $86 million following the disclosure of positive results in the phase 3 clinical trial of CAN-2409 in localized prostate cancer in December 2024. In January 2025, he was promoted to Senior VP. During his time at Candel, Mr. Schoch has built a high-performing finance function that oversees Candel's financial close process, internal controls, SEC reporting, financial planning, procurement, payroll, and treasury operations. Mr. Schoch has also worked closely with Candel's executive leadership team on investor relations, business development, and financing initiatives.
Prior to joining Candel, Mr. Schoch served as Corporate Controller at Corbus Pharmaceuticals from 2019 to 2021. Before Corbus, he spent seven years in PwC's Health Industry assurance practice where he served a diverse group of audit clients, ranging from pre-IPO to multinational public companies within the life sciences sector. Earlier in his career, Mr. Schoch worked for several Third Rock Venture portfolio companies as a financial and operational consultant. Mr. Schoch holds an M.B.A. and M.S.A. from Northeastern University and a B.S. in business administration with a concentration in finance from Elon University.
'I am honored to continue serving in this role and excited about the opportunities that lie ahead for Candel,' commented Mr. Schoch. 'Our strong financial foundation and disciplined approach to capital allocation and value creation position us well for sustainable growth. As we advance our promising clinical pipeline and prepare for key milestones, my focus remains on maintaining financial stability while strategically investing in our future. I look forward to working with our talented team on our goals of driving value for our stakeholders and ultimately helping to deliver clinically meaningful solutions to cancer patients in need.'
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform.
The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA most recently also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, expectations regarding the submission of the BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
Jury orders Tesla to pay more than $240 million in Autopilot crash case
MIAMI (AP) — A Miami jury decided that Elon Musk's car company Tesla was partly responsible for a deadly crash in Florida involving its Autopilot driver assist technology and must pay the victims more than $200 million in damages. The federal jury held that Tesla bore significant responsibility because its technology failed and that not all the blame can be put on a reckless driver, even one who admitted he was distracted by his cell phone before hitting a young couple out gazing at the stars. The decision comes as Musk seeks to convince Americans his cars are safe enough to drive on their own as he plans to roll out a driverless taxi service in several cities in the coming months. The decision ends a four-year long case remarkable not just in its outcome but that it even made it to trial. Many similar cases against Tesla have been dismissed and, when that didn't happen, settled by the company to avoid the spotlight of a trial. 'This will open the floodgates,' said Miguel Custodio, a car crash lawyer not involved in the Tesla case. 'It will embolden a lot of people to come to court.' The case also included startling charges by lawyers for the family of the deceased, 22-year-old, Naibel Benavides Leon, and for her injured boyfriend, Dillon Angulo. They claimed Tesla either hid or lost key evidence, including data and video recorded seconds before the accident. Tesla has previously faced criticism that it is slow to cough up crucial data by relatives of other victims in Tesla crashes, accusations that the car company has denied. In this case, the plaintiffs showed Tesla had the evidence all along, despite its repeated denials, by hiring a forensic data expert who dug it up. Tesla said it made a mistake after being shown the evidence and honestly hadn't thought it was there. 'Today's verdict is wrong," Tesla said in a statement, 'and only works to set back automotive safety and jeopardize Tesla's and the entire industry's efforts to develop and implement life-saving technology,' They said the plaintiffs concocted a story 'blaming the car when the driver – from day one – admitted and accepted responsibility.' In addition to a punitive award of $200 million, the jury said Tesla must also pay $43 million in compensatory damages, bringing the total borne by the company to $243 million. 'It's a big number that will send shockwaves to others in the industry,' said financial analyst Dan Ives of Wedbush Securities. 'It's not a good day for Tesla.' Tesla said it will appeal. It's not clear how much of a hit to Tesla's reputation for safety the verdict in the Miami case will make. Tesla has vastly improved its technology since the crash on a dark, rural road in Key Largo, Florida, in 2019. But the issue of trust generally in the company came up several times in the case, including in closing arguments Thursday. The plaintiffs' lead lawyer, Brett Schreiber, said Tesla's decision to even use the term Autopilot showed it was willing to mislead people and take big risks with their lives because the system only helps drivers with lane changes, slowing a car and other tasks, falling far short of driving the car itself. Schreiber said other automakers use terms like 'driver assist' and 'copilot' to make sure drivers don't rely too much on the technology. 'Words matter,' Schreiber said. 'And if someone is playing fast and lose with words, they're playing fast and lose with information and facts.' Schreiber acknowledged that the driver, George McGee, was negligent when he blew through flashing lights, a stop sign and a T-intersection at 62 miles an hour before slamming into a Chevrolet Tahoe that the couple had parked to get a look at the stars. The Tahoe spun around so hard it was able to launch Benavides 75 feet through the air into nearby woods where her body was later found. It also left Angulo, who walked into the courtroom Friday with a limp and cushion to sit on, with broken bones and a traumatic brain injury. But Schreiber said Tesla was at fault nonetheless. He said Tesla allowed drivers to act recklessly by not disengaging the Autopilot as soon as they begin to show signs of distraction and by allowing them to use the system on smaller roads that it was not designed for, like the one McGee was driving on. 'I trusted the technology too much,' said McGee at one point in his testimony. 'I believed that if the car saw something in front of it, it would provide a warning and apply the brakes.' The lead defense lawyer in the Miami case, Joel Smith, countered that Tesla warns drivers that they must keep their eyes on the road and hands on the wheel yet McGee chose not to do that while he looked for a dropped cell phone, adding to the danger by speeding. Noting that McGee had gone through the same intersection 30 or 40 times previously and hadn't crashed during any of those trips, Smith said that isolated the cause to one thing alone: 'The cause is that he dropped his cell phone.' The auto industry has been watching the case closely because a finding of Tesla liability despite a driver's admission of reckless behavior would pose significant legal risks for every company as they develop cars that increasingly drive themselves.
Globe and Mail
an hour ago
- Globe and Mail
AXT (AXTI) Q2 Revenue Drops 36%
Key Points Non-GAAP loss per share widened to ($0.15) versus estimates of ($0.13), reflecting soft demand and margin compression. Positive movement seen in indium phosphide (InP) substrate shipments linked to early artificial intelligence demand, but not enough to offset broader weakness. These 10 stocks could mint the next wave of millionaires › AXT (NASDAQ:AXTI), a specialty materials producer known for high-performance semiconductor substrates, reported second-quarter 2025 earnings on July 31, 2025. The headline news from the release was a sharper-than-expected revenue decline, as GAAP revenue was $18.0 million, missing the analysts' estimate of $19.78 million by $1.78 million, or 9.0%, with non-GAAP earnings falling short of market estimates amid ongoing pressure from regulatory delays and a slow demand environment in China. GAAP revenue was $18.0 million, missing the $19.8 million GAAP analyst estimate, while non-GAAP loss per share was ($0.15), instead of the expected ($0.13) (non-GAAP). The quarter's overall performance showed persistent challenges, with some improvement in gross margin from the prior period but continued losses and steep year-over-year declines (GAAP gross margin 8.0%, up from (6.4)% in Q1 2025 and down from 27.4% in Q2 2024; non-GAAP gross margin 8.2%, up from (6.1)% in Q1 2025 and down from 27.6% in Q2 2024). Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) ($0.15) ($0.13) ($0.02) (650.0%) Revenue (GAAP) $18.0 million N/A $27.9 million (35.5%) Gross Margin (Non-GAAP) 8.2% 27.6% (19.4 pp) Net Loss (Non-GAAP) ($6.4 million) ($0.8 million) 700.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. About AXT: Business Overview and Strategic Focus AXT manufactures compound semiconductor substrates such as gallium arsenide (GaAs), indium phosphide (InP), and germanium (Ge). These substrates serve as foundational materials in products for the data center, wireless, 5G, LED, and automotive sectors. Its products are used in applications such as artificial intelligence, optical networking, and advanced sensing. The company has recently focused on strengthening its position in high-growth areas like AI-driven optical interconnects, where efficient data processing and transmission are key. Maintaining a vertically integrated supply chain and pushing for advanced substrate quality have also become central, as has managing exposure to geopolitical and regulatory headwinds in China. Successfully expanding manufacturing scale and securing export permits remain crucial factors going forward. Quarter in Review: Revenue Declines, Margin Recovery, and Emerging Demand Trends This was also a sequential decline from the previous period's $19.4 million GAAP revenue. GAAP revenue came in $1.8 million below analyst expectations. Management attributed this shortfall mostly to longer processing times for gallium arsenide export permits and a sluggish demand environment in China. Raw material sales also faced pressure from these trends. While non-GAAP gross margin improved from negative territory in the previous quarter to 8.2%, this still lagged well behind last year's non-GAAP gross margin of 27.6%. The partial margin recovery reflects some success in process and operational improvements, though it remains well below optimal levels due to lower sales volume and ongoing cost challenges. One positive development for the business was the growth in substrate shipments for AI-related applications. Indium phosphide (InP) substrates, essential for high-speed optical data transmission in data centers and advanced computing, saw increased demand in China. Management pointed to its first successful exports of InP substrates outside China following new export permit approvals in June. Even so, these gains did not offset widespread softness in other end markets. Geopolitical and regulatory obstacles, especially related to China, were major themes this quarter. The delay and complexity of export permit processes weighed on expected sales, as did continued uncertainties in the broader Chinese economy. The ongoing regulatory review for the company's STAR Market IPO—the planned public offering of its subsidiary Tongmei in China—remains unresolved. Business Drivers, Product Lines, and Key Risks AXT's performance relies on the demand for high-quality substrates in data-intensive and high-speed applications. Its key product types—gallium arsenide, indium phosphide, and germanium substrates—are used for things like 5G base stations, lasers for data centers, and high-efficiency solar cells. Success in offering superior technical specifications, like low etch pit density (a measure of crystal quality), helps the company meet evolving customer requirements for next-generation devices. The company operates a vertically integrated supply chain, with partial ownership of raw material companies in China. This setup should, in theory, help with pricing, supply reliability, and cost control. However, increased operational costs and limited flexibility amid falling revenue have highlighted the balance between integration benefits and the risks of heavy concentration in China. Regulatory and trade restrictions remain a material risk, as delays in exporting key substrate products impact revenue and growth plans. No explicit dividend was declared this quarter, aligning with the company's current practice. Looking Ahead: Guidance and Investor Focus Instead, it underscored a focus on improving operational efficiency, supporting next-generation technology needs, and working to expand access to markets outside China as new export permits are granted. There are some early signs of demand recovery tied to AI-driven uses for InP substrates, but these remain small relative to the company's overall scale and current headwinds. Investors should watch for developments around external orders for high-speed substrates, trends in inventory and cash flow, and any updates on the STAR Market IPO for Tongmei. The company's ability to access capital and scale production as demand recovers will be critical. AXT does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of July 29, 2025
CTV News
an hour ago
- CTV News
Trump fires U.S. Labour Department's statistical leader after weaker than expected jobs report
WASHINGTON — U.S President Donald Trump on Friday ordered that the commissioner of the U.S. Bureau of Labor Statistics, Erika L. McEntarfer, be fired after data showed employment growth was weaker than expected last month. McEntarfer was nominated by former President Joe Biden to serve in the role in 2023 and was confirmed by the U.S. Senate the following year. 'We need accurate Jobs Numbers. I have directed my Team to fire this Biden Political Appointee, IMMEDIATELY. She will be replaced with someone much more competent and qualified,' Trump said in a post on Truth Social. (Reporting by Jasper Ward; Editing by Chris Reese)
